Abstract:Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS), are relatively common and devastating neurological disorders. For example, there are 6 million individuals living with AD in the United States, a number that is projected to grow to 14 million by the year 2030. Importantly, AD, PD and MS are all characterized by the lack of a true disease-modifying therapy that is able to reverse or halt disease progression. In addition, the existing standard of care for most NDs only addresses the symptoms of the disease. Therefore, alternative strategies that target mechanisms underlying the neuropathogenesis of disease are much needed. Recent studies have indicated that metabolic alterations in neurons and glia are commonly observed in AD, PD and MS and lead to changes in cell function that can either precede or protect against disease onset and progression. Specifically, single-cell RNAseq studies have shown that AD progression is tightly linked to the metabolic phenotype of microglia, the key immune effector cells of the brain. However, these analyses involve removing cells from their native environment and performing measurements in vitro, influencing metabolic status. Therefore, technical approaches that can accurately assess cell-specific metabolism in situ have the potential to be transformative to our understanding of the mechanisms driving AD. Here, we review our current understanding of metabolism in both neurons and glia during homeostasis and disease. We also evaluate recent advances in metabolic imaging, and discuss how emerging modalities, such as fluorescence lifetime imaging microscopy (FLIM) have the potential to determine how metabolic perturbations may drive the progression of NDs. Finally, we propose that the temporal, regional, and cell-specific characterization of brain metabolism afforded by FLIM will be a critical first step in the rational design of metabolism-focused interventions that delay or even prevent NDs.

Glycometabolic Reprogramming of Microglia in Neurodegenerative Diseases: Insights from Neuroinflammation

The role of microglia immunometabolism in neurodegeneration: Focus on molecular determinants and metabolic intermediates of metabolic reprogramming

Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

The immunometabolic reprogramming of microglia in Alzheimer's disease

Fueling neurodegeneration: metabolic insights into microglia functions

Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

Target modulation of glycolytic pathways as a new strategy for the treatment of neuroinflammatory diseases

Mitochondrial Dysfunction in Microglia: a Novel Perspective for Pathogenesis of Alzheimer’s Disease

Altered substrate metabolism in neurodegenerative disease: new insights from metabolic imaging

Microglia Phenotypes in Aging and Neurodegenerative Diseases

Metabolic Regulation of Glia and Their Neuroinflammatory Role in Alzheimer's Disease

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Metabolic Reprograming of Microglia in the Regulation of the Innate Inflammatory Response

Microglia in Neurodegenerative Diseases

Therapeutic approaches to microglial dysfunction in Alzheimer's disease: Enhancing phagocytosis and metabolic regulation

Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system

The Neuro-Inflammatory Microenvironment: An Important Regulator of Stem Cell Survival in Alzheimer's Disease

New insight on microglia activation in neurodegenerative diseases and therapeutics

Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders